 |
|
|
| |
FIRST REAL-WORLD DATA ON SAFETY AND EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: DATA FROM THE GERMAN HEPATITIS C-REGISTRY
|
| |
| |
Reported by Jules Levin
EASL - 53rd Annual Meeting of the European Association for the Study of the Liver
Paris, France
13 April 2018
Thomas Berg1, Uwe Naumann4, Albrecht Stoehr5, Christoph Sick6, Gerlinde Teuber7, Willibold Schiffelholz8, Stefan Mauss9, Jan Hettinger3, Henning Kleine3, Andreas Pangerl3, Claus Niederau2
1Section of Hepatology, Clinic of Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany; 2. Katholisches Klinikum Oberhausen, St. Josef-Hospital, Klinik fur Innere Medizin,
Akademisches Lehrkrankenhaus der Universität Duisburg-Essen, Oberhausen, Germany; 3. AbbVie Inc., North Chicago, Illinois, U.S.A; 4. UBN-Praxis , Berlin, Germany; 5. IFI Studien und Projekte GmbH, Hamburg, Germany; 6. Praxisonkologie Bremen, Bremen, Germany; 7. Practice PD Dr. med. G. Teuber, Frankfurt am Main, Germany; 8. Gastroenterologische Schwerpunktpraxis, Augsburg, Germany; 9. Center for HIV and Hepatogastroenterology, Dusseldorf, Germany
|
| |
|
|
|
|
|
